论文部分内容阅读
目的:评价干扰素联合化疗治疗非小细胞肺癌的疗效,为临床提供参考。方法:检索1988～2008年发表的相关文献并按照统一标准入选,评价指标为1年生存率、缓解率、白细胞减少发生率与血小板减少发生率;采用RevMan4.2软件进行Meta分析,二分类变量用RR值与95%CI表示。结果:干扰素联合化疗组与单纯化疗组的Meta分析显示,1年生存率未见显著性差异、缓解率差异有统计学意义、白细胞减少发生率差异有统计学意义、血小板减少发生率差异有统计学意义。结论:干扰素联合化疗在非小细胞肺癌治疗中并不能提高患者的生存率,而且增加患者的白细胞和血小板减少的发生率,故在临床上应慎用。
Objective: To evaluate the efficacy of interferon combined with chemotherapy in the treatment of non-small cell lung cancer and provide reference for clinical practice. Methods: The related literatures published from 1988 to 2008 were searched and selected according to unified criteria. The evaluation indexes were 1-year survival rate, remission rate, incidence of leukopenia and thrombocytopenia. Meta-analysis was performed with RevMan4.2 software. The dichotomous variables RR value and 95% CI said. Results: Meta-analysis showed that there was no significant difference in 1-year survival rate between the interferon combined chemotherapy group and the chemotherapy alone group, the difference was statistically significant, the difference of the incidence of leukopenia was statistically significant, the difference of thrombocytopenia rate was Statistical significance. Conclusion: Interferon combined with chemotherapy in non-small cell lung cancer therapy does not improve the survival rate of patients, and increase the incidence of leukopenia and thrombocytopenia in patients, it should be used with caution in clinical.